Skip to main content

Attovia Therapeutics, Inc.

ATTO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002058707

In the last 90 days, Attovia Therapeutics, Inc. insiders filed 5 open-market purchases and 1 sale; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Holders of 5% or more of ATTO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Attovia Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ATTO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Frazier Life Sciences Public Fund, L.P.13D13.50%6.15M sharesNewAug 11, 20261 filingAug 11, 2026SEC
Deep Track Capital, LP13G7.45%3.21M sharesNewAug 12, 20261 filingAug 12, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Attovia Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ATTO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 12, 20264:02 PM ETDeep Track Capital, LPand 2 others13G7.45%3.21M sharesNewAug 5, 2026SEC
Aug 11, 20265:08 PM ETFrazier Life Sciences Public Fund, L.P.and 8 others13D13.50%6.15M sharesNewAug 6, 2026SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Attovia Therapeutics, Inc. shares.

No Form 144 notices for Attovia Therapeutics, Inc. are on file.